BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2019

Jan 30, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2019-01-28

Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-28	Common Stock	M	5000	$5.45	Acquired	133426	Direct
2019-01-28	Common Stock	S	5000	$9.85	Disposed	128426	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-28	Emp. Stock Option (Right to Buy)	$5.45	M	5000	Disposed	2023-08-08	Common Stock (5000)	Direct

Footnotes

F1: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018.